The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: A systematic review

Although acute oxaliplatin-induced neuropathy (OXIPN) is frequently regarded to be transient, recent studies have reported prolongation of infusion times, dose reduction and treatment cessation following the first dose of oxaliplatin in quarter of patients.